Background: P426L and I179S are the two most frequent mutations in juvenile and adult metachromatic leukodystrophy (late-onset MLD), which, in contrast to infantile MLD, show marked phenotypic heterogeneity. Objective: To search for genotype-phenotype correlations in late-onset MLD. Methods: The authors reviewed the clinical course of 22 patients homozygous for mutation P426L vs 20 patients heterozygous for mutation I179S, in which the second arylsulfatase A (ASA) mutation had also been determined. Results: P426L homozygotes principally presented with progressive gait disturbance caused by spastic paraparesis or cerebellar ataxia; mental disturbance was absent or insignificant at the onset of disease but became more apparent as the disease evolved. In contrast, compound heterozygotes for I179S presented with schizophrenia-like behavioral abnormalities, social dysfunction, and mental decline, but motor deficits were scarce. Reduced peripheral nerve conduction velocities and less residual ASA activity were present in P426L homozygotes vs I179S heterozygotes. Conclusion: The characteristic clinical differences between homozygous P426L and compound heterozygous I179S patients establish a distinct genotype-phenotype correlation in late-onset metachromatic leukodystrophy.
notype variation, regardless of the kind of 0 mutation. In contrast, marked clinical heterogeneity is found in late-onset (late juvenile and adult) MLD associated with the two late-onset genotypes (0/R and R/R). Among these, two different clinical presentations have been observed: patients with progressive motor or sensory deficits and, on the other hand, cases with mental disturbance. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] It has been suggested that these differences may originate from different specific mutations. 1, 7, 12 To explore a possible genotype-phenotype correlation in late-onset MLD on the basis of specific mutations, we studied the molecular and clinical data of 22 patients homozygous for mutation P426L and of 20 patients heterozygous for mutation I179S. These two mutations are the most frequent R-type mutations in late-onset MLD.
Methods. Patients. We studied MLD patients with either mutation P426L in homozygosity or mutation I179S in heterozygosity when adequate biochemical and clinical data were available. In the I179S patients, the second mutation was also characterized. Twenty-one unpublished and 21 reported patients [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] fulfilled these criteria and were included (22 P426L homozygotes and 20 I179S compound heterozygotes) (see tables E-1 and E-2 on the Neurology Web site; go to www.neurology.org). In all patients, diagnosis of MLD was verified biochemically by determination of ASA activity in leukocytes or fibroblasts, sulfatide excretion in urine, or neuropathologic examination of nerve biopsy. As, owing to the low incidence of late-onset MLD and the paucity of cases recognized in the early clinical phase, a prospective approach is almost impossible, acquisition of clinical data were done retrospectively. All available clinical records of the hitherto unpublished patients were examined by experienced neurologists who could not be blinded to the genotype. The reviewer abstracted each symptom and sign given in the records to obtain an individual chronology for each patient. Similarly, the clinical courses of the reported cases were abstracted by one reviewer; in 10 cases, unpublished clinical data were provided by the respective authors.
Biochemical analysis. ASA activity was determined in leukocytes 23, 24 and in urine. 25 ASA activities are reported as percentage of the mean ASA reference values.
Genetic analysis. In the 21 new patients and in the previously published cases, genomic DNA was extracted by standard procedures either from leukocytes or from fibroblasts. 26 Detection of the mutations P426L and I179S was performed by PCR restriction assays as previously described. 13, 27 In 12 cases, mutation I179S was confirmed by sequencing.
To identify the complete genotype, both strands of the PCR fragment containing each of the eight ASA exons were sequenced in nine cases. The primers and laboratory methods are given in table E-3 and appendix E-1.
Statistical analysis. Nonparametric tests (e.g., Mann-Whitney) were used to compare clinical data between genotypes. Data were expressed as means Ϯ SEM; unless stated otherwise, p values of Ͻ0.05 were considered significant.
Results. The complete molecular and clinical data of the 42 patients investigated are available in tables E-1 and E-2.
Genetic analysis. Our own PCR-based investigations on the common ASA mutations P426L and I179S revealed 13 cases homozygous for mutation P426L and 8 cases heterozygous for the I179S ASA allele. In the other cases, mutations were given as reported in the literature. To characterize the second ASA mutation in nine heterozygotes for I179S, the entire coding ASA sequence was analyzed. In six cases, the common splice site mutation 459 ϩ 1 G¡A known to be a 0-type ASA allele was identified. In two patients, a G-to-C transversion was identified at posi-tion 1,100, leading to the D255H substitution, and a C-to-G transversion at nucleotide 1,067 was identified in one patient, leading to the missense mutation R244C. Both mutations can be considered as 0-type mutation as both have been described in patients with late infantile MLD previously. 28, 29 Among the 12 additional I179S heterozygotes already reported in the literature, 8 have a second mutation, which belongs to the ASA 0-type: 5 with 459 ϩ 1G¡A, 1 with 1,204 ϩ 1G¡A, 1 with A212V, and 1 with L135P. In one patient, I179S was associated with D281Y, which has never been observed at the homozygous state or in any other combination than with I179S and thus cannot be categorized as a 0-or R-type mutation. 10 In three patients, the I179S allele was associated with P426L, a well-known R-type allele.
Eight patients, all carrying I179S/459 ϩ 1G¡A, shared three polymorphisms: T391S (2,161 C¡G) in exon 7, 2,213 C¡G in intron 7, and W193C (842 G¡T) in exon 3. The 2,213 C¡G and T391S polymorphisms have also been found in two patients carrying as second mutation D255H. In addition, polymorphism 2,213 C¡G has been detected in one patient carrying R244C and polymorphism T391S in one patient carrying 459 ϩ 1G¡A as second mutation (tables E-1 and E-2).
Genotype-phenotype correlations. Clinical syndromes at onset and in advanced disease are summarized in figures 1 and 2. The phenotype and genotype of each patient are available in tables E-1 and E-2, and two characteristic cases are presented in appendix E-2.
Patients homozygous for p426l. Two cases were still asymptomatic at ages 14 and 32, both with symptomatic siblings. Age at onset was variable in the 20 patients (11 males, nine females) and ranged from 10 to 29 years (mean 19.9 Ϯ 1.3 years). This classifies 14 cases as adult and 6 cases as late juvenile MLD. 1 Documented disease course ranged from 1 to 20 years (mean 6.7 Ϯ 1.2 years).
Sixteen of the 20 patients presented with progressive gait disturbance due to spastic paraparesis or cerebellar ataxia. In seven cases, gait disturbance was accompanied by cognitive disturbance, personality changes (apathy, loss of spontaneity), or disorganized behavior, in two by visual loss due to optic atrophy, and in one by epilepsy. In an advanced course of the disease, cognitive decline was observed in 18 patients and marked frontal lobe-type personality changes in 3 of the 20 patients. Symptoms of brainstem dysfunction (noncerebellar dysarthria, dysphagia, gaze palsy) developed in three patients, extrapyramidal symptoms (bradykinesia, athetosic movements) in two, and seizures in three patients.
Only four patients did not have gait disturbance at onset. Two of them presented with paravertebral pain: one with progressive optic atrophy and one with apathy and cognitive deficits initially diagnosed as major depression. In the further course, progressive spastic paraparesis and cerebellar ataxia as well as cognitive disturbance developed in three of these patients.
Two patients had sensory impairment: one with hemihypesthesia and one with a symmetric sensory deficit in the distal lower limbs developing 20 years after onset, very probably due to excessive alcohol consumption.
Otherwise, symptoms or clinical signs of PNS damage were generally absent.
Patients heterozygous for I179s. Age at onset in the 20 patients (11 males, 9 females) ranged from 8 to 60 years (mean 26 Ϯ 3.0 years). This is statistically not different from the mean age at onset in the P426L homozygotes. Sixteen I179S heterozygotes were classified as adult and four as late juvenile MLD. 1 The mean age at onset in the 3 patients with an R-type mutation on the second allele (47 Ϯ 6.3 years) was higher (p Ͻ 0.01) than in the 16 patients with a 0-type mutation (22.4 Ϯ 2.6 years). Documented disease course ranged from 1 to 23 years (mean 7.8 Ϯ 5.3 years).
Nineteen of the 20 patients presented with isolated neuropsychiatric symptoms and 1 patient with a combination of neuropsychiatric symptoms and gait disturbance. The initial neuropsychiatric symptoms were prominent behavioral and perceptual disturbances that are described for schizophrenia in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders, namely, delusions and hallucinations in 3 patients, disorganized behavior in 12 patients, and social dysfunction in all. In addition, nine patients had signs of a frontal lobe syndrome: lack of social inhibition, emotional lability, or apathy. In the further course there was cognitive decline in 19 patients, leading to dementia in 7 cases, 4 to 14 years (median 7 years) after onset. Five patients were hospitalized in psychiatric institutions mainly with the diagnosis of schizophrenia until neurologic signs appeared or because the atypical course of the disease led to the performance of cerebral MRI. The majority of patients with isolated mental symptoms at onset developed neurologic disturbances 2 to 14 years (median 7 years) after onset: Seven patients had spastic or ataxic motor impairment, two patients epileptic seizures, and three patients had localized cortical disturbances such as aphasia, agraphia, acalculia, apraxia, or agnosia. Extrapyramidal symptoms, brainstem disturbances, optic atrophy, action and postural tremor, or unspecified gait disturbance developed in one patient. Eight cases did not develop any neurologic signs or symptoms, despite a disease duration of up to 23 years. Symptoms or clinical signs of PNS damage were generally absent.
Neuroimaging. In P426L homozygotes, results of cerebral CT were available in 16 cases and of cerebral MRI in 11 cases. In I179S heterozygotes, results of cerebral CT and MRI were available in 7 and 11 cases. Both groups, symptomatic as well as asymptomatic cases, showed the classic signs of leukodystrophy with symmetric periventricular white matter abnormalities and relative sparing of U-fibers, accompanied by cortical and subcortical atrophy. Two P426L homozygous patients showed signs of long fiber tract degeneration in brainstem MRI images. Brainstem changes were generally absent in the I179S patients, but in seven of them, white matter changes were frontally accentuated.
Electrophysiology. Nerve conduction studies were performed in 19 of 20 symptomatic P426L homozygotes, and a prolonged or severely prolonged nerve conduction velocity was generally found. Numerical data were available in 13 patients. Nerve conduction studies were done in 14 of 20 I179S heterozygotes. Numerical data were available in eight patients. In a further six patients, slightly reduced nerve conduction velocities were found. Mean motor nerve conduction velocity was slower in the upper limbs in P426L homozygotes (32 Ϯ 1.9 m/s) than in I179S heterozygotes (42 Ϯ 3.1 m/s; p Ͻ 0.02). In the lower limbs, differences were more pronounced (23 Ϯ 0.9 m/s in P426L homozygotes vs 37 Ϯ 3.1 m/s in I179S heterozygotes; p Ͻ 0.0005) ( figure E-1) . The time between disease onset and nerve conduction studies was not statistically different between the two groups. There was no correlation of nerve conduction velocity with disease duration at the time of examination.
EEG was available in seven P426L homozygotes and in four I179S heterozygotes. In both groups, diffuse slowing was most common, but focal slowing as well as focal epileptiform elements were additional findings.
CSF. Results of CSF analysis were available in 12 P426L homozygotes and 8 I179S heterozygotes. Cell count was generally normal, but protein was mildly elevated in about half of patients in both groups (range 0.46 to 0.73 g/L).
ASA activity. Mean ASA activity control values were available for 14 P426L homozygotes and 12 I179S heterozygotes, all with a 0-mutation on the second allele. In the remaining cases, ASA activity was below the range of control values (mean not known).
Although there is considerable overlap, the mean leukocyte ASA activity was lower in P426L homozygotes (5.8 Ϯ 1.0%) than in I179S compound heterozygotes (10.6 Ϯ 1.7%) (p Ͻ 0.03) ( figure E-2 ).
Discussion.
In this study, we present late-onset MLD patients with fully analyzed genotypes and characterize two distinct phenotypes, correlating with the ASA mutations P426L and I179S.
P426L homozygotes typically started with gait disturbance caused by spastic paraparesis or cerebellar ataxia, whereas all patients heterozygous for mutation I179S presented with inappropriate or disorganized behavior and social dysfunction. Because of the isolated psychiatric presentation and the relatively young age at onset, the patients are at risk to be misdiagnosed as having schizophrenia or affective disorder.
In early disease, the clinical syndrome of patients heterozygous for I179S is distinct and different from that of patients homozygous for P426L ( figure 1 ). However, in advanced disease, the two groups become clinically less distinct, as a combination of neurologic and neuropsychiatric disturbances is then often found in patients of both genotypes (figure 2).
Although nerve conduction studies show more severe changes in P426L homozygotes than in I179S heterozygotes, considerable overlap limits the clinical usefulness of these findings.
Neuroimaging also did not differentiate the two groups, although it is of interest that frontal dominance of the leukoencephalopathy was found in a proportion of I179S heterozygotes, but not in P426L homozygotes. It has been suggested that in patients with psychocognitive MLD, the prefrontal white matter is primarily involved, implying that psychosis in MLD is related in particular to a functional impairment of prefrontal temporolimbic connections. 30 Alternatively, the psychiatric presentation might be caused by cortical dysfunction, because when compared with changes in late infantile MLD, a relatively increased sulfatide accumulation in the cortical gray matter has been found in a patient with adult MLD with predominant mental disturbance. 31 Considering the presence of two apparently identical mutant ASA alleles in P426L homozygotes, there is still remarkable heterogeneity of the clinical expression. This emphasizes the influence of the genetic background or unknown environmental factors. In contrast, I179S heterozygotes, harboring diverse heteroallelic ASA variants, show a remarkably consistent phenotype. The I179S allele was mainly asso-ciated with 0-type ASA alleles, which, in the homozygous state, causes late infantile MLD. If the I179S mutation was associated with an R-allele, this led to a significantly older age at onset than the association with a 0-allele, but otherwise the phenotype was essentially the same. Therefore, and as no patients with MLD homozygous for I179S have been detected up to now, a high residual ASA activity of this enzyme variant has to be expected. Mean leukocyte ASA activity in our I179S heterozygotes was significantly higher than in the P426L homozygotes, but the range was large with nearly complete overlap. As the correlation of leukocyte ASA activity to the relevant ASA activity in neurons and glia is unknown, leukocyte ASA activities do not permit conclusions regarding the clinical course of the individual patient. 32 Figure 2 . Symptoms in advanced disease in P426L homozygous and I179S heterozygous patients with metachromatic leukodystrophy. White bars ϭ P426L homozygotes; black bars ϭ I179S compound heterozygotes; *declining visual acuity due to optic nerve atrophy, paravertebral pain, epilepsy, localized cortical disturbances as aphasia, agraphia, acalculia, apraxia, or agnosia, brainstem dysfunction, noncerebellar tremor; **lack of social inhibition, loss of interest, apathy ("frontal lobe type").
